Sangamo Therapeutics, Inc. (LON:0R1D)
0.5127
+0.0125 (2.50%)
At close: Sep 16, 2025
Sangamo Therapeutics Revenue
Sangamo Therapeutics had revenue of $18.31M USD in the quarter ending June 30, 2025, with 5,042.13% growth. This brings the company's revenue in the last twelve months to $81.71M, up 565.52% year-over-year. In the year 2024, Sangamo Therapeutics had annual revenue of $57.80M, down -67.20%.
Revenue (ttm)
$81.71M
Revenue Growth
+565.52%
P/S Ratio
1.90
Revenue / Employee
$446.48K
Employees
183
Market Cap
113.22M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 57.80M | -118.43M | -67.20% |
Dec 31, 2023 | 176.23M | 64.93M | 58.34% |
Dec 31, 2022 | 111.30M | 598.00K | 0.54% |
Dec 31, 2021 | 110.70M | -7.49M | -6.34% |
Dec 31, 2020 | 118.19M | 15.76M | 15.39% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Sangamo Therapeutics News
- 5 days ago - Sangamo Therapeutics (SGMO) Shares Decline Following CFO Resignation News - GuruFocus
- 5 days ago - Sangamo Therapeutics falls on CFO retirement - Seeking Alpha
- 13 days ago - SGMO: HC Wainwright Reiterates Buy Rating at $10 Price Target | SGMO Stock News - GuruFocus
- 13 days ago - Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025 - GlobeNewsWire
- 5 weeks ago - Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Sangamo Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 5 weeks ago - Sangamo Therapeutics GAAP EPS of -$0.08 misses by $0.04, revenue of $18.3M misses by $13.38M - Seeking Alpha
- 5 weeks ago - Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results - GlobeNewsWire